Research Article
GASC1-Adapted Neoadjuvant Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma: A Prospective Clinical Biomarker Trial
Table 2
Patient evaluation characteristics after neoadjuvant chemotherapy.
| | Characteristics | GASC1 | | | High (n = 24, %) | Low (n = 36, %) | Total (n = 60) |
| | ypT | | | | | | T0 | 0 | 6 (16.7) | 6 | <0.001 | | Carcinoma in situ | 0 | 3 (8.3) | 3 | | T1 | 1 (4.2) | 7 (19.4) | 8 | | T2 | 2 (8.4) | 9 (25) | 11 | | T3 | 10 (41.7) | 8 (22.2) | 18 | | T4 | 11 (45.8) | 3 (8.3) | 14 | | ypN | | | | | | N0 | 9 (37.5) | 28 (77.8) | 37 | 0.002 | | N+ | 15 (62.5) | 8 (22.2) | 23 | | Pathological stage | | | | | | I | 2 (8.3) | 14 (38.9) | 16 | 0.002 | | II | 5 (20.8) | 12 (33.3) | 17 | | III | 13 (54.2) | 10 (27.8) | 23 | | IVA | 4 (16.7) | 0 | 4 | | Histologic grade | | | | | | G1 | 4 (16.7) | 17 (47.2) | 21 | <0.001 | | G2 | 10 (41.7) | 18 (50) | 29 | | G3 | 10 (41.7) | 1 (2.8) | 10 | | Response | | | | | | CT evaluation | | | | | | CR | 0 | 9 (25) | 9 | 0.006 | | PR | 8 (33.3) | 16 (44.4) | 24 | | SD | 13 (54.2) | 11 (30.6) | 24 | | PD | 3 (12.5) | 0 | 3 | | TRG | | | | | | 1 | 0 | 6 (16.7) | 6 | 0.006 | | 2 | 5 (20.8) | 15 (41.7) | 20 | | 3 | 14 (58.3) | 13 (36.1) | 27 | | 4 + 5 | 5 (20.8) | 2 (5.6) | 7 | | Surgical resection | | | | | | R0 | 18 (75) | 34 (94.4) | 52 | 0.046 | | R1 | 5 (20.8) | 2 (5.6) | 7 | | R2 | 1 (4.2) | 0 | 1 | | TRG | | | | | | 1 | 0 | 6 (16.7) | 6 | 0.072 | | 2–4 | 24 (100) | 30 (83.3) | 54 | | ORR | | | | | | CR + PR | 8 (33.3) | 25 (69.4) | 33 | 0.006 | | SD + PD | 16 (66.7) | 11 (30.6) | 27 |
|
|
